中國先鋒醫藥(01345.HK)擬向美國公司銷售1850萬美元KN95防護口罩
格隆匯6月4日丨中國先鋒醫藥(01345.HK)發佈公告,集團最近與一家總部位於美國的公司(“買方”)達成協議,據此,買方同意購買KN95防護口罩。銷售額合共1850萬美元及銷售事項預計大約於2020年7月初或之前完成。
隨着2019冠狀病毒病大流行於全球各地肆虐,據報醫療物資出現短缺。集團樂於在此困境支援需要幫助的人士,而作為一項舉措,一直在探求辦法幫助應對對口罩的迫切需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.